Orforglipron UK statistics 2026

Orforglipron is an oral GLP-1 receptor agonist developed by Eli Lilly and branded as Foundayo in the United States. It is designed to be taken once daily as a tablet, without the food or water restrictions required by oral semaglutide (Rybelsus). By mid-2026, orforglipron had completed six phase 3 trials in the ATTAIN programme (for obesity and overweight) and the ACHIEVE programme (for type 2 diabetes), and received FDA approval for chronic weight management in adults with obesity or overweight in April 2026. However, it is not yet licensed by the MHRA or appraised by NICE in the UK, so no official UK price or NHS access route exists as of July 2026.

ATTAIN programme weight-loss outcomes

The ATTAIN programme investigated orforglipron in adults with obesity or overweight, with and without type 2 diabetes. ATTAIN-1 enrolled adults with obesity or overweight but no diabetes, and ATTAIN-2 enrolled adults with obesity or overweight plus cardiometabolic risk factors or type 2 diabetes. Both trials were 72-week, randomised, double-blind, placebo-controlled studies.

In ATTAIN-1, the highest orforglipron dose (36 mg once daily) produced a mean weight loss of approximately 12.4% at 72 weeks, compared to around 0.9% with placebo. Nearly 60% of participants on the highest dose achieved at least 10% weight loss, and around 40% achieved at least 15% weight loss. In ATTAIN-2, orforglipron 36 mg once daily produced a mean weight loss of 10.5% (22.9 lb) compared to 2.2% (5.1 lb) with placebo at 72 weeks. All three orforglipron doses in ATTAIN-2 met primary and main secondary endpoints, with improvements in HbA1c and cardiometabolic risk factors described qualitatively in the press release.

ACHIEVE programme diabetes control outcomes

The ACHIEVE programme investigated orforglipron in adults with type 2 diabetes. Six phase 3 trials were completed by mid-2026, including ACHIEVE-1, ACHIEVE-2, ACHIEVE-3, ACHIEVE-5, and ACHIEVE-4. ACHIEVE-2 compared orforglipron to dapagliflozin, ACHIEVE-3 compared orforglipron to oral semaglutide, ACHIEVE-5 added orforglipron to insulin glargine, and ACHIEVE-4 assessed cardiovascular outcomes vs insulin glargine.

In ACHIEVE-2, orforglipron doses of 3 mg, 12 mg, and 16 mg once daily produced HbA1c reductions of 1.3%, 1.7%, and 1.7% respectively at 40 weeks, compared to 0.8% with dapagliflozin. In ACHIEVE-3, a head-to-head comparison with oral semaglutide in adults with type 2 diabetes on metformin, orforglipron produced greater HbA1c and weight reductions. The higher orforglipron dose achieved approximately 1.9% HbA1c reduction and 9.2% weight loss, but also had higher rates of GI-related adverse-event discontinuation (around 9.7%) compared to oral semaglutide (around 4.5 to 4.9%). In ACHIEVE-5, orforglipron added to insulin glargine produced HbA1c reductions of 1.5%, 2.1%, and 1.9% across doses, compared to 0.8% with placebo plus insulin glargine.

ACHIEVE-4 cardiovascular outcomes

ACHIEVE-4 was a cardiovascular outcomes trial enrolling more than 2,700 adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The primary objective was to demonstrate non-inferiority vs insulin glargine for main cardiovascular outcomes. Topline results reported by Clarivate in April 2026 showed that orforglipron met non-inferiority and demonstrated a 16% lower risk of MACE-4 (major adverse cardiovascular events including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalisation for unstable angina), a 23% lower risk of MACE-3 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), and a 57% lower risk of all-cause death compared to insulin glargine. These outcomes are expected to support regulatory submissions for type 2 diabetes indications.

Safety and tolerability profile

Trial summaries describe a safety profile consistent with injectable GLP-1 medicines, including gastrointestinal adverse events such as nausea, diarrhoea, vomiting, and reduced appetite. In ACHIEVE-3, adverse-event-related discontinuation was higher with orforglipron (around 8.7 to 9.7%) than with oral semaglutide (around 4.5 to 4.9%). ATTAIN-2 reported that the safety profile was consistent with injectable GLP-1 medicines, with no new safety signals identified. Detailed adverse-event breakdowns and rates by dose would require the full NEJM and Lancet publications for ATTAIN-1 and ACHIEVE-3.

Global regulatory timeline and FDA approval

Eli Lilly announced in late 2025 that it had completed the full clinical data package required to initiate global regulatory submissions for orforglipron for obesity, and planned to submit for type 2 diabetes in 2026 following completion of ACHIEVE-4. The US FDA approved orforglipron (branded as Foundayo) for chronic weight management in adults with obesity or overweight in April 2026, based on the ATTAIN programme data. Lilly stated that it planned to submit for type 2 diabetes by the end of Q2 2026, using ACHIEVE-4 cardiovascular outcomes data.

UK MHRA and NICE status as of July 2026

As of July 2026, no MHRA licence or NICE technology appraisal for orforglipron appears in available sources. Secondary UK commentary from health information hubs and online pharmacies suggests that MHRA submission is expected around mid-2026, with potential approval and private-prescription availability from late 2026 to 2027. One source explicitly claims that the MHRA approved orforglipron on 11 June 2026, but this is not corroborated by MHRA or NICE primary publications in the available public result. Verification requires checking the MHRA product licensing database directly. NHS reimbursement would depend on a NICE technology appraisal, which has not been published as of July 2026.

UK patients and clinicians tracking orforglipron should check the MHRA product licensing database for marketing authorisation status and date, and the NICE website for technology appraisal scope and final guidance. The NIHR published a health technology briefing in October 2025 on ATTAIN-OSA, a phase 3 trial investigating orforglipron in participants with obstructive sleep apnoea and obesity or overweight, indicating UK HTA interest, but this does not constitute a licensing decision.

Comparison with other GLP-1 medications

Orforglipron is the first oral GLP-1 receptor agonist to receive FDA approval for obesity, and the first to be designed without food or water restrictions. Oral semaglutide (Rybelsus) is an oral GLP-1 approved for type 2 diabetes, but must be taken fasting with a small volume of water and strict timing. Injectable GLP-1 medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) have higher mean weight-loss percentages in their registration trials based on pre-2024 data, but require subcutaneous injection. Precise comparative figures from UK-relevant sources would require NICE appraisals and primary trial publications.

Practical tracking and preparation for UK patients and clinicians

Because MHRA and NICE have not yet published definitive documents on orforglipron, tracking relies on checking the MHRA product licensing database to confirm whether orforglipron (Foundayo) receives a UK marketing authorisation, and on what date, and checking the NICE website to see if and when NICE evaluates orforglipron for obesity or type 2 diabetes. The NIHR published a health technology briefing in October 2025 on ATTAIN-OSA, showing where orforglipron features in UK HTA pipelines, but this does not constitute a licensing decision.

If orforglipron becomes available in the UK, patients and clinicians may want to focus on whether the licensed indication covers obesity alone, obesity with comorbidities, type 2 diabetes, or multiple conditions; whether there are specific intake conditions; how weight and A1c reductions in ATTAIN and ACHIEVE compare to existing GLP-1 injectables using primary trial data and NICE appraisals; rates and types of adverse events in ATTAIN and ACHIEVE, especially GI events, AE-related discontinuation, and cardiovascular outcomes; and whether access is likely via private prescriptions initially, as suggested by UK commentary, or whether NHS reimbursement follows NICE evaluation. Patients and clinicians should rely on MHRA, NICE, and peer-reviewed trial publications rather than secondary summaries for final decisions.

Source coverage and methodology

this guide is based on primary and near-primary sources where available, including corporate scientific summaries from Eli Lilly, sponsor press releases announcing main trial results and regulatory plans, conference programme documents such as the ADA 2026 Lilly PDF describing ACHIEVE-2, ACHIEVE-3, and ACHIEVE-5, and the NIHR health technology briefing for ATTAIN-OSA. Secondary research digests and market intelligence from Clarivate Drugs-to-Watch and RetaLABS research guide collate phase 3 trial statistics and references to NEJM and Lancet publications. UK-focused commentary sources from Envigore, HealthCount, QuickMeds, and Let's Lose Weight provide speculative MHRA and NICE timelines and access routes.

Where exact numbers such as placebo arm weight loss or precise semaglutide values are reported only by secondary sources, they are treated as approximate and flagged for validation against primary journal articles. Regulatory status in the UK is described conservatively because no MHRA or NICE primary documents were available in the public result. Claims of MHRA approval are treated as unverified without direct MHRA documentation. MHRA and NICE sites were not directly available in the public result, so no primary UK regulatory documents could be cited. Pricing and reimbursement data for orforglipron in the UK do not appear in the 2026 public result; any UK price or NHS coverage statements would require official MHRA, NICE, or NHS documents. Global comparators such as Wegovy and Mounjaro rely partly on pre-2024 knowledge; for rigorous comparison, one would need to pull current NEJM or Lancet trial publications and NICE HTA reports.